4042095

Source:http://linkedlifedata.com/resource/pubmed/id/4042095

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005525, umls-concept:C0008976, umls-concept:C0205390, umls-concept:C0920321, umls-concept:C1274040, umls-concept:C1707689
pubmed:issue	10
pubmed:dateCreated	1985-11-13
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7607107
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Biological Agents
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0361-5960
pubmed:author	pubmed-author:PinskyC MCM
pubmed:issnType	Print
pubmed:volume	69
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1171-3
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:4042095-Antineoplastic Agents, pubmed-meshheading:4042095-Biological Agents, pubmed-meshheading:4042095-Clinical Trials as Topic, pubmed-meshheading:4042095-Combined Modality Therapy, pubmed-meshheading:4042095-Drug Administration Schedule, pubmed-meshheading:4042095-Drug Evaluation, pubmed-meshheading:4042095-Humans, pubmed-meshheading:4042095-Neoplasms, pubmed-meshheading:4042095-Research Design
pubmed:year	1985
pubmed:articleTitle	Applicability of phase I trial results in the design of phase II and III biological response modifier trials.
pubmed:publicationType	Journal Article